N-(4-aminobenzoyl)-L-glutamic acid

We are N-(4-aminobenzoyl)-L-glutamic acid CAS:4271-30-1 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

N-(4-aminobenzoyl)-L-Glutamic acid,Folic Ac
Folic acid impurity A
(S)-2-(4-Aminobenzamido)pentanedioic acid
(p-aminobenzoyl)-L-glutamic acid
N-(4-Aminobenzoyl)-L-glutamic Acid
L-Glutamic acid, N-(4-aminobenzoyl)-
N-(p-Aminobenzoyl)glutamic acid
N-p-aminobenzoyl-L-glutamic acid
4-aminobenzoyl-L-glutamic acid
Molecular Formula: C12H14N2O5
Molecular Weight: 266.25000
Appearance and properties: beige crystalline powder
Density: 1.418 g/cm3
Boiling point: 607.1ºC at 760 mmHg
Melting point: ~175 °C (dec.)
Flash point: 320.9ºC
Refractive index: 1.617
Storage conditions: -20ºC
Applications: Pharmaceutical intermediates, used in the production of methotrexate and folic acid.

Items of Analysis Standard of Analysis Test Results
Appearance White crystalline powder Conform
Melting point 168-174℃ 172.8-173.4℃
Assay (HPLC) ≥98.0% 99.89%
Loss on drying ≤2.0% 0.34%
Residue on ignition ≤3.0% 1.10%
Conclusion Conforms to Factory Standard


N-(4-aminobenzoyl)-L-glutamic acid

Related News: The acquired pharmaceutical intermediates business will be renamed Corden Pharma Switzerland LLC and will operate as part of ICIG’s pharmaceutical business within the Corden Pharma platform. The companies’ goal is to close the transaction during the first quarter of 2011. Financial terms are not disclosed.2-methyl-1-hydroxy-3-butanone oxime With the continuous accumulation of the API industry and the increasing maturity of the market, competition in China’s API industry will become increasingly fierce.4-chloro-3-propoxy-butyric acid propyl ester The KCDC said a 28-year-old man had tested positive. He was among the 368 repatriated South Koreans who arrived from Wuhan on a charter flight on January 31. The rest of the evacuees have tested negative for the coronavirus.62253-63-8 GlaxoSmithKline (GSK) is at the bottom of the top 20 list with the lowest percentage R&D spend/annual revenue at 12%.”Fate Therapeutics’ iPSC product platform is supported by an intellectual property portfolio of over 250 issued patents and 150 pending patent applications.

Related Products
Product Name
1,3-Dichloroacetone Cas:534-07-6 View Details
2-Chlorophenylboronic acid Cas:138642-62-3 View Details
3-(2-Bromo-4,5-dimethoxyphenyl)-2-cyanopropionic Acid Cas:41234-20-2 manufacturer TOSYL ISOCYANATE Cas:4083-64-1 manufacturer Isobutylboronic Acid manufacturer 4,4′-bis(2-methoxystyryl)biphenyl Cas:40470-68-6 manufacturer 3-Fluoro-2-methylphenol manufacturer